Literature DB >> 22593799

Exploring molecular pathways of triple-negative breast cancer.

Valeria Ossovskaya1, Yipeng Wang, Adam Budoff, Qiang Xu, Alexander Lituev, Olga Potapova, Gordon Vansant, Joseph Monforte, Nikolai Daraselia.   

Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a high rate of proliferation and metastasis, as well as poor prognosis for advanced-stage disease. Although TNBC was previously classified together with basal-like and BRCA1/2-related breast cancers, genomic profiling now shows that there is incomplete overlap, with important distinctions associated with each subtype. The biology of TNBC is still poorly understood; therefore, to define the relative contributions of major cellular pathways in TNBC, we have studied its molecular signature based on analysis of gene expression. Comparisons were then made with normal breast tissue. Our results suggest the existence of molecular networks in TNBC, characterized by explicit alterations in the cell cycle, DNA repair, nucleotide synthesis, metabolic pathways, NF-κB signaling, inflammatory response, and angiogenesis. Moreover, we also characterized TNBC as a cancer of mixed phenotypes, suggesting that TNBC extends beyond the basal-like molecular signature and may constitute an independent subtype of breast cancer. The data provide a new insight into the biology of TNBC.

Entities:  

Keywords:  DNA repair; NF-κB; cell cycle; molecular pathways; triple-negative breast cancer (TNBC); tumor metabolism

Year:  2011        PMID: 22593799      PMCID: PMC3352156          DOI: 10.1177/1947601911432496

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  36 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression.

Authors:  Christian Boehler; Laurent R Gauthier; Oliver Mortusewicz; Denis S Biard; Jean-Michel Saliou; Anne Bresson; Sarah Sanglier-Cianferani; Susan Smith; Valérie Schreiber; François Boussin; Françoise Dantzer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

Review 3.  Human DNA repair genes, 2005.

Authors:  Richard D Wood; Michael Mitchell; Tomas Lindahl
Journal:  Mutat Res       Date:  2005-09-04       Impact factor: 2.433

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 5.  A review of triple-negative breast cancer.

Authors:  Roohi Ismail-Khan; Marilyn M Bui
Journal:  Cancer Control       Date:  2010-07       Impact factor: 3.302

Review 6.  Breast cancer as a global health concern.

Authors:  Steven S Coughlin; Donatus U Ekwueme
Journal:  Cancer Epidemiol       Date:  2009-11-07       Impact factor: 2.984

7.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

8.  Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.

Authors:  Hee Sung Kim; Cha Kyong Yom; Hee Jeong Kim; Jong Won Lee; Jin Hee Sohn; Jun Ho Kim; Yong Lai Park; Sei Hyun Ahn
Journal:  Breast Cancer Res Treat       Date:  2009-10-06       Impact factor: 4.872

Review 9.  The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.

Authors:  A E Roussidis; A D Theocharis; G N Tzanakakis; N K Karamanos
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

10.  Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Pablo Moscato
Journal:  PLoS One       Date:  2008-09-03       Impact factor: 3.240

View more
  35 in total

1.  PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.

Authors:  Jennifer Stanley; Lisa Klepczyk; Kimberly Keene; Shi Wei; Yufeng Li; Andres Forero; William Grizzle; Monica Wielgos; Jason Brazelton; Albert F LoBuglio; Eddy S Yang
Journal:  Breast Cancer Res Treat       Date:  2015-04-02       Impact factor: 4.872

2.  Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.

Authors:  Yan Liu; Qiuyin Cai; Ping-Ping Bao; Yinghao Su; Hui Cai; Jie Wu; Fei Ye; Xingyi Guo; Wei Zheng; Ying Zheng; Xiao-Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2015-06-11       Impact factor: 4.872

Review 3.  Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.

Authors:  Citra Dewi; Adryan Fristiohady; Riezki Amalia; Nur Kusaira Khairul Ikram; Sugeng Ibrahim; Muchtaridi Muchtaridi
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

4.  Predictors of early distant metastasis in women with breast cancer.

Authors:  Erick Sta Rosa Mendoza; Emmanuel Moreno; Priscilla Baetiong Caguioa
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

5.  Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.

Authors:  Michelle L Baglia; Qiuyin Cai; Ying Zheng; Jie Wu; Yinghao Su; Fei Ye; Ping-Ping Bao; Hui Cai; Zhiguo Zhao; Justin Balko; Wei Zheng; Wei Lu; Xiao-Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2014-10-04       Impact factor: 4.872

6.  SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Authors:  Antonio Llombart-Cussac; Begoña Bermejo; Cristian Villanueva; Suzette Delaloge; Serafín Morales; Judith Balmaña; Kepa Amillano; Hervé Bonnefoi; Ana Casas; Luis Manso; Henri Roché; Santiago Gonzalez-Santiago; Joaquín Gavilá; Pedro Sánchez-Rovira; Serena Di Cosimo; Nadia Harbeck; Eric Charpentier; Ignacio Garcia-Ribas; Nina Radosevic-Robin; Claudia Aura; Jose Baselga
Journal:  Breast Cancer Res Treat       Date:  2015-11-04       Impact factor: 4.872

7.  Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

Authors:  Sophia B Chernikova; Rochelle B Nguyen; Jessica T Truong; Stephano S Mello; Jason H Stafford; Michael P Hay; Andrew Olson; David E Solow-Cordero; Douglas J Wood; Solomon Henry; Rie von Eyben; Lei Deng; Melanie Hayden Gephart; Asaithamby Aroumougame; Claudia Wiese; John C Game; Balázs Győrffy; J Martin Brown
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808

Review 8.  Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Authors:  Fanny Le Du; Bedrich L Eckhardt; Bora Lim; Jennifer K Litton; Stacy Moulder; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Naoto T Ueno
Journal:  Oncotarget       Date:  2015-05-30

9.  Role of SMC1 in overcoming drug resistance in triple negative breast cancer.

Authors:  Sushma Yadav; Archana Sehrawat; Zeynep Eroglu; George Somlo; Robert Hickey; Sailee Yadav; Xueli Liu; Yogesh C Awasthi; Sanjay Awasthi
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis.

Authors:  Valentina Pileczki; Cornelia Braicu; Claudia D Gherman; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2012-12-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.